Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology. “We understand that ...